LianBio
LianBio (LIANY): 3 pipeline candidates · 1 upcoming catalyst · ~47 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
46.6 months
D/E 0.13 · 0% dilution
Lead: Phase 3
3 candidates
1 upcoming, next in ~3098d
N/A
A transparent, data-derived signal for LianBioacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$12.2M
Cash
$103.5M
Quarterly Burn
$15.9M
Runway
46.6 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| infigratinib | Phase 2 |
| nbtxr3 | Phase 3 |
| tp-03 | Phase 3 |
Upcoming Catalysts (1)
Frequently asked questions
How many drug candidates are in LianBio's pipeline?
LianBio (LIANY) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is LianBio's lead drug candidate?
LianBio's most advanced tracked candidate is infigratinib (Phase 2) for gastric cancer and other FGFR-driven tumors.
What is LianBio's next catalyst?
LianBio's next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: TRUSELTIQ" — expected December 11, 2034.
What is LianBio's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, LianBio has approximately 46.6 months of cash runway.
What is LianBio's market capitalization?
LianBio's market capitalization is approximately $12.2M.
Get the full picture on LianBio
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.